Could a breath test replace finger pricks for diabetes?
NCT ID NCT07696273
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This study tests a small, noninvasive device that analyzes breath to detect high and low blood sugar events in children and young adults with diabetes. Participants aged 7–25 who already use a continuous glucose monitor will provide breath samples during normal, high, and low blood sugar periods. The goal is to see if the sensor can accurately estimate glucose levels without finger sticks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Miniaturized breath sensing device
- What this could lead to
- If successful, this could lead to a painless, noninvasive way for people with diabetes to monitor their blood sugar levels using just their breath.
- What could go wrong
- This is a small, early-stage study with only 40 participants. The device's accuracy is still being tested, and it may not work as well in real-world settings or for all age groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
7 to 25 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Who are diagnosed with T1D or T2D. * Who are between 7-25 years of age. * That use a Dexcom (G6 or G7) CGM device. * That have an established working CGM for at least 12 hours. * That are willing to share their CGM data for the study duration. * That are willing and able to fill up a breath collection bag. * That are attending a diabetes camp in the state of Indiana. Exclusion Criteria: * That are smokers or who live with someone who smokes in their vicinity (including prior to attending camp). * That have a condition or abnormality other than T1D/T2D that in the opinion of the Investigators would compromise the safety of the subject or the quality of the data. * That have symptoms or recently been diagnosed with an upper respiratory illness including COVID-19 (or other viral/bacterial infections). * That follow a "ketogenic diet". * That are unable or unwilling to cooperate with either of the sample collection modes.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Jameson Camp
RECRUITINGIndianapolis, Indiana, 46231, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Clinical and biological responses to repeated administration of low-dose Interleukin-2 in patients with type 1 diabetes and a residual insulin secretion
- Cost-Effectiveness and implementation of integrated Diabetes-Oral health care in oman: a health belief Model-Based intervention to enhance clinical, behavioral, and exploratory oral microbiome in health system outcomes in type 2 diabetes
- Fibrinogen to albumin ratio (FAR) as a risk factor for type 2 diabetic Nephropathy(DN)
- Can a smart insulin pump tailored for pregnancy protect mothers and babies?
- Which insulin dosing method keeps hospital blood sugar in check?
- Can an automated pancreas system make type 1 diabetes safer in the real world?